Skip to main content
Equibles

BDRX · Biodexa Pharmaceuticals Plc

Track BDRX — free

Use BDRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BDRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.39 -0.02 (-5.27%)
Rebalance outlook locked
Market Cap
$896,022
Shares
2.20M
Volume · Oct 22 96.37K Avg daily vol (3M) 4.86M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.41 Open$0.40 Day$0.39–0.42 52W close$0.35–44.00 Avg vol 30d9.8M Short int18K · 0.8% float · 1.0d Short vol29% Last earningsJun 30, 2021 DataJan 2020–Oct 2026

Up next

Q2 2021 earnings call transcript
Date not confirmed

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-45.5%
Year over year
Operating margin
-2,103.4%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-1,034.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+33,675.1%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
0.8%
Latest settlement · 1.0 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 19 · elevated Equity put/call 0.69
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −88%
below
Price vs 50-day avg −49%
below
RSI (14) 36
neutral
MACD trend Positive
52-week position 0%
near low
Volume (OBV) Bullish div.
accumulating
Momentum
relative strength
Very Weak
1-month return −39%
trailing
6-month return −86%
trailing
YTD return −96%
this year
Relative strength −92%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $1 › 200d $4 — 200d above 50d
Institutional flow Distributing
2 of 8 funds reported for Sep 30 · net -1.2K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.83% of float · ▼ -93.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
8 holders — mid 3-yr range
Squeeze score 29
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 203%
annualized · 1-yr
Max drawdown −99%
past year
ATR 22.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
3 · 2 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−88% Bearish
Price vs 50-day avg
−49% Bearish
RSI (14)
36 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Volume (OBV)
Bullish div. Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $1 › 200d $4 — 200d above 50d
Institutional flow Distributing
2 of 8 funds reported for Sep 30 · net -1.2K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
0.83% of float · ▼ -93.2% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
8 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $44
vs 200-day avg -88% vs 50-day avg -49%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
BDRX
Biodexa Pharmaceuticals Plc
this stock
$896,022 — — — 0.8%
VRTX
Vertex Pharmaceuticals Inc
 $136.14B +18.0% +46.2% 31.3 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $82.95B +6.1% +20.8% 20.0 2.1%
MRNA
Moderna, Inc.
 $80.90B +587.1% +4.3% — 7.7%
CSLLY
Csl Ltd
 $65.88B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
7
% held
0.7%
Reported
2 of 8
Top holder
ARMISTICE CAPITAL, LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
18.4K
Days to cover
1.0d
Change
-253.5K sh
View
Short Volume
Short vol %
29%
As of
Oct 22, 2026
Short Total
View
Fails to Deliver
FTD shares
1.1K
Value
$694
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
42.3%
Week of
Sep 14, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
6-K
Filed
Oct 14, 2026
This year
20

Biodexa enrolled 100 patients in the registrational Phase 3 Serenta trial of eRapa for Familial Adenomatous Polyposis. A futility analysis could occur early next year after 25 Progression Free Survival events, with database lock potentially around next year-end after 75 events.

View
Exempt Offerings
Offering
$5.0M
Filed
Aug 1, 2024
View
Earnings & Events
Webcasts
Last webcast
Jun 30, 2021
View

Performance

5D 20D 120D MTD YTD
BDRX -4.0% -38.7% -86.3% -36.9% -96.4%
SPY -1.0% -0.4% +6.0% +0.2% +12.0%
vs SPY -3.0% -38.3% -92.4% -37.1% -108.4%
Key facts CIK 1643918 CUSIP 59564R872 13F (30d) 1 filings 1 filers Visit website Investor relations